SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharma stocks slip on Donald Trump’s targeted attack

12 Jan 2017 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 2997.00, down by 50.35 points or 1.65% from its previous closing of Rs. 3047.35 on the BSE. The scrip opened at Rs. 3000.00 and has touched a high and low of Rs. 3020.10 and Rs. 2941.00 respectively. So far 31951 shares were traded on the counter.

Lupin is currently trading at Rs. 1503.95, down by 16.35 points or 1.08% from its previous closing of Rs. 1520.30 on the BSE. The scrip opened at Rs. 1508.00 and has touched a high and low of Rs. 1520.00 and Rs. 1490.00 respectively. So far 79415 shares were traded on the counter.

Sun Pharmaceutical Industries is currently trading at Rs. 638.15, down by 9.55 points or 1.47% from its previous closing of Rs. 647.70 on the BSE. The scrip opened at Rs. 632.00 and has touched a high and low of Rs. 643.50 and Rs. 628.00 respectively. So far 197142 shares were traded on the counter.

Glenmark Pharmaceuticals is currently trading at Rs. 902.15, down by 2.00 points or 0.22 % from its previous closing of Rs. 904.15 on the BSE. The scrip opened at Rs. 897.00 and has touched a high and low of Rs. 905.00 and Rs. 889.95 respectively. So far 11381 shares were traded on the counter.

Pharma stocks came under pressure after US president-elect Donald Trump attacked the pharmaceutical industry for high drug prices and for manufacturing overseas, saying he will create new procedures for bidding on drugs, reports AFP. Trump also said the pharmaceutical companies are getting away with murder.

Dr. Reddys Lab Share Price

1220.75 -11.50 (-0.93%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×